MX2022009219A - Mezclas de cannabidiol que no cristalizan. - Google Patents

Mezclas de cannabidiol que no cristalizan.

Info

Publication number
MX2022009219A
MX2022009219A MX2022009219A MX2022009219A MX2022009219A MX 2022009219 A MX2022009219 A MX 2022009219A MX 2022009219 A MX2022009219 A MX 2022009219A MX 2022009219 A MX2022009219 A MX 2022009219A MX 2022009219 A MX2022009219 A MX 2022009219A
Authority
MX
Mexico
Prior art keywords
cbda
cbd
crystallizing
cannabidiol
blends
Prior art date
Application number
MX2022009219A
Other languages
English (en)
Inventor
Matthew Moore
William Lanier
Andrew Horvath
Scott Davis
Josh Eldridge
James Hook
Original Assignee
Chemtor Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemtor Lp filed Critical Chemtor Lp
Publication of MX2022009219A publication Critical patent/MX2022009219A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Abstract

Una mezcla que no cristaliza incluye cannabidiol (CBD) y ácido cannabidiólico (CBDA). Un método para formar una mezcla que no cristaliza de CBD y CBDA incluye obtener un aislado de CBD que incluye al menos 80 % en peso de CBD, obtener un aislado de CBDA que incluye al menos 80 % en peso de CBDA, y combinar y mezclar el aislado de CBD y el CBDA. Un método para tratar una afección incluye administrar una cantidad terapéuticamente eficaz de una mezcla que no cristaliza de CBD y CBDA a un paciente en necesidad del mismo.
MX2022009219A 2020-01-27 2021-01-26 Mezclas de cannabidiol que no cristalizan. MX2022009219A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062966333P 2020-01-27 2020-01-27
PCT/US2021/015074 WO2021154719A1 (en) 2020-01-27 2021-01-26 Non-crystallizing cannabidiol blends

Publications (1)

Publication Number Publication Date
MX2022009219A true MX2022009219A (es) 2022-09-29

Family

ID=76970837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009219A MX2022009219A (es) 2020-01-27 2021-01-26 Mezclas de cannabidiol que no cristalizan.

Country Status (5)

Country Link
US (2) US11648219B2 (es)
EP (1) EP4097022A4 (es)
CA (1) CA3166156A1 (es)
MX (1) MX2022009219A (es)
WO (1) WO2021154719A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022232574A1 (en) * 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
US20230097799A1 (en) * 2021-09-29 2023-03-30 Chemtor L.P. Full spectrum hemp oil compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
DK2760444T3 (da) 2011-09-29 2020-07-27 Thc Pharm Gmbh The Health Concept Cannabinoidcarboxylsyrer, salte af cannabinoidcarboxylsyrer, fremstilling og anvendelse deraf
US9340475B2 (en) 2014-07-02 2016-05-17 Cv Sciences, Inc. Process for generating hemp oil with a high cannabidiol (CBD) content
EP3253727A4 (en) * 2015-02-05 2018-08-08 Colorado Can LLC Purified cbd and cbda, and methods, compositions and products employing cbd or cbda
US20170008870A1 (en) 2015-07-06 2017-01-12 Clare J. Dibble Methods for Obtaining Purified Cannabis Extracts and THCA Crystals
BR112019019966A2 (pt) 2017-03-24 2020-04-28 Trait Biosciences Inc biossíntese in vivo de alto nível e isolamento de canabinoides solúveis em água em sistemas de plantas
US11905543B2 (en) 2017-07-11 2024-02-20 Trait Biosceinces, Inc. In vivo generation of water-soluble acetylated cannabinoid glycoside compounds in plant cell suspension cultures
WO2019056123A1 (en) 2017-09-22 2019-03-28 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN
WO2019161231A1 (en) * 2018-02-16 2019-08-22 Botanical Process Solutions LLC Use of non-crystalline terpene alcohols for the inhibition of crystallization of cannabinoids

Also Published As

Publication number Publication date
US20230226001A1 (en) 2023-07-20
EP4097022A1 (en) 2022-12-07
EP4097022A4 (en) 2024-02-28
US20210228513A1 (en) 2021-07-29
CA3166156A1 (en) 2021-08-05
US11648219B2 (en) 2023-05-16
WO2021154719A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
MX2022009219A (es) Mezclas de cannabidiol que no cristalizan.
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
MX339658B (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa.
MX2021006094A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
NZ718955A (en) Compositions comprising povidone-iodine
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
BRPI0514357A (pt) combinações para o tratamento de doenças que envolvem a proliferação de células
MX2021009646A (es) Uso de cannabinoides en el tratamiento de epilepsia.
WO2008089268A3 (en) Methods and compositions for treating conditions associated with infection and/or inflammation
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
WO2017037534A1 (en) Topical compositions for treatment of psoriasis
YU2703A (sh) Bistar vodeni anestetski preparat
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
CN103908491B (zh) 一种治疗脚气脚臭的组合物及其制备方法
WO2019195761A3 (en) Pharmacological agents for treating ocular diseases
CN103330650A (zh) 一种滋润去屑止痒组合物
MX2022001429A (es) Formulaciones que incluyen dihidrohonokiol.
CN111166694A (zh) 一种舒缓修护保湿面膜液及其制备方法
MX2022007720A (es) Extractos enriquecidos con compuestos polifenolicos y metodos relacionados.
DE202005020103U1 (de) Nahrungsergänzungsmittel
MY197721A (en) Composition and uses thereof
CN107617102A (zh) 一种治疗鸡球虫病的中药添加剂组合物
CN106577809A (zh) 一种农药增效剂
DE202012100195U1 (de) Neue Verwendung einer pharmazeutischen Zusammensetzung, enthaltend Ancrod